Burns J W & Co INC Cut Its Stake in Bristol (BMY) by $3.58 Million

November 10, 2018 - By Clifton Ray

Bristol-Myers Squibb Company (NYSE:BMY) LogoInvestors sentiment decreased to 0.78 in Q2 2018. Its down 0.05, from 0.83 in 2018Q1. It fall, as 94 investors sold BMY shares while 550 reduced holdings. 108 funds opened positions while 396 raised stakes. 1.14 billion shares or 1.65% more from 1.12 billion shares in 2018Q1 were reported. Guyasuta Investment Advisors holds 0.22% or 34,130 shares. Moreover, Hartford has 0.37% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 214,182 shares. Blair William And Company Il holds 674,381 shares or 0.25% of its portfolio. Polaris Greystone Fincl Gru Limited Liability, a California-based fund reported 341,773 shares. Apg Asset Management Nv holds 0.23% in Bristol-Myers Squibb Company (NYSE:BMY) or 2.59M shares. Connor Clark & Lunn Ltd holds 639,591 shares or 0.2% of its portfolio. Peapack Gladstone Corp accumulated 312,123 shares. Wealthtrust Fairport Limited Liability Co has 2,833 shares for 0.02% of their portfolio. Hbk Sorce Advisory Limited Liability Corp holds 22,208 shares. Ibm Retirement Fund, New York-based fund reported 34,102 shares. 194,389 are held by Sectoral Asset Mgmt. Alpha Cubed Investments reported 10,544 shares. Gamble Jones Invest Counsel reported 0.59% stake. Stralem & Company stated it has 17,800 shares. Outfitter Limited stated it has 0.18% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY).

Burns J W & Co Inc decreased its stake in Bristol (BMY) by 46.05% based on its latest 2018Q2 regulatory filing with the SEC. Burns J W & Co Inc sold 65,024 shares as the company’s stock rose 12.85% with the market. The institutional investor held 76,176 shares of the major pharmaceuticals company at the end of 2018Q2, valued at $4.22M, down from 141,200 at the end of the previous reported quarter. Burns J W & Co Inc who had been investing in Bristol for a number of months, seems to be less bullish one the $87.14B market cap company. The stock increased 1.10% or $0.58 during the last trading session, reaching $53.39. About 8.11 million shares traded or 13.28% up from the average. Bristol-Myers Squibb Company (NYSE:BMY) has declined 4.27% since November 10, 2017 and is downtrending. It has underperformed by 19.89% the S&P500.

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Seekingalpha.com which released: “Bristol-Myers Squibb beats by $0.18, misses on revenue” on October 24, 2018, also Seekingalpha.com with their article: “Recent Purchase: Bristol-Myers Squibb” published on October 29, 2018, Seekingalpha.com published: “Bristol-Myers Squibb’s Opdivo flunks late-stage lung cancer study” on October 12, 2018. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Seekingalpha.com and their article: “Infinity Pharma teams up with Bristol-Myers Squibb in urothelial cancer” published on November 05, 2018 as well as Seekingalpha.com‘s news article titled: “BMS Is A Buy On The Dip” with publication date: October 31, 2018.

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

Among 9 analysts covering Bristol Myers (NYSE:BMY), 2 have Buy rating, 0 Sell and 7 Hold. Therefore 22% are positive. Bristol Myers had 10 analyst reports since May 21, 2018 according to SRatingsIntel. As per Monday, October 8, the company rating was maintained by JP Morgan. The rating was upgraded by Atlantic Securities on Wednesday, August 8 to “Neutral”. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Hold” rating by UBS on Monday, May 21. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Equal-Weight” rating by Morgan Stanley on Tuesday, November 6. As per Tuesday, October 23, the company rating was maintained by BMO Capital Markets. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Market Perform” rating by BMO Capital Markets on Monday, July 23. On Friday, July 27 the stock rating was maintained by Credit Suisse with “Neutral”. Citigroup downgraded Bristol-Myers Squibb Company (NYSE:BMY) rating on Monday, October 22. Citigroup has “Neutral” rating and $57 target. Barclays Capital maintained the stock with “Equal-Weight” rating in Friday, October 12 report.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.